{
    "clinical_study": {
        "@rank": "58667", 
        "arm_group": [
            {
                "arm_group_label": "Cohort A - Triple negative breast cancer", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive pembrolizumab, 10 mg/kg, intravenously (IV) once every 2 weeks, and will continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years)"
            }, 
            {
                "arm_group_label": "Cohort B - Head/neck cancer", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive pembrolizumab, 10 mg/kg, intravenously (IV) once every 2 weeks, and will continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years)"
            }, 
            {
                "arm_group_label": "Cohort C - Urothelial tract cancer", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive pembrolizumab, 10 mg/kg, intravenously (IV) once every 2 weeks, and will continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years)"
            }, 
            {
                "arm_group_label": "Cohort D - Gastric cancer", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive pembrolizumab, 10 mg/kg, intravenously (IV) once every 2 weeks, and will continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years)"
            }, 
            {
                "arm_group_label": "Cohort B2 - Head/neck cancer", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive pembrolizumab, 200 mg, intravenously (IV) once every 3 weeks, and will continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years)"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is being done to investigate the safety, tolerability and anti-tumor activity of\n      pembrolizumab (MK-3475) in participants with advanced triple negative breast cancer (TNBC)\n      (Cohort A), advanced head and neck cancer (Cohorts B and B2), advanced urothelial cancer\n      (Cohort C), or advanced gastric cancer (Cohort D)"
        }, 
        "brief_title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cancer", 
            "Solid Tumor"
        ], 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Amendment 2 of the protocol added a new study arm (Cohort B2) for participants with advanced\n      head and neck cancer who will receive a lower dose of pembrolizumab (MK-3475) every three\n      weeks (Q3W);  participants with programmed cell death ligand 1 (PD-L1)-negative tumors will\n      also be analyzed separately."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically-confirmed diagnosis of tumor that is recurrent,\n             metastatic, or persistent:\n\n               -  For Cohort A - triple negative breast cancer (estrogen, progesterone, and human\n                  epidermal growth factor receptor 2 [HER2] negative)\n\n               -  For Cohort B - squamous cell carcinoma of the head and neck (including\n                  HPV-positive head and neck squamous cell cancer).\n\n               -  For Cohort C - urothelial tract cancer of the renal pelvis, ureter, bladder, or\n                  urethra (transitional cell or non-transitional cell histology)\n\n               -  For Cohort D - adenocarcinoma of the stomach or gastroesophageal junction\n\n               -  For Cohort B2 - squamous cell carcinoma of the head and neck (both HPV-positive\n                  and -negative head and neck squamous cell cancer)\n\n          -  Any number of prior treatment regimens\n\n          -  Measurable disease\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1\n\n          -  Female participants of childbearing potential must be willing to use 2 methods of\n             birth control or be surgically sterile, or abstain from heterosexual activity for the\n             course of the study through 120 days after the last dose of study treatment\n\n          -  Male participants must agree to use an adequate method of contraception starting with\n             the first dose of study therapy through 120 days after the last dose of study\n             treatment\n\n        Exclusion Criteria:\n\n          -  Currently participating in/has participated in a study of an investigational agent or\n             using an investigational device within 4 weeks of the first dose of study treatment\n\n          -  Diagnosis of immunosuppression or receiving systemic steroid therapy or any other\n             form of immunosuppressive therapy within 7 days prior to the first dose of study\n             treatment\n\n          -  Anti-cancer monoclonal antibody treatment within 4 weeks prior to study Day 1 or not\n             recovered from adverse events due to agents administered more than 4 weeks earlier\n\n          -  Chemotherapy, targeted small molecule therapy or radiation therapy within 2 weeks\n             prior to study Day 1 or not recovered from adverse events due to a previously\n             administered agent\n\n          -  Known additional malignancy that is progressing or requires active treatment\n             excepting basal cell carcinoma of the skin, squamous cell carcinoma of the   skin, or\n             in situ cervical cancer that has undergone potentially curative therapy\n\n          -  Known active central nervous system (CNS) metastases and/or carcinomatous meningitis\n\n          -  Active autoimmune disease requiring systemic treatment within the past 3 months or\n             documented history of clinically severe autoimmune disease, or syndrome that requires\n             systemic steroids or immunosuppressive agents\n\n          -  Evidence of interstitial lung disease\n\n          -  Active infection requiring systemic therapy\n\n          -  Known psychiatric or substance abuse disorders\n\n          -  Pregnant, breastfeeding, or expecting to conceive or father children within the\n             projected duration of the trial, starting with the pre-screening or screening visit\n             through 120 days after the last dose of trial treatment\n\n          -  Prior therapy with an anti-programmed cell death 1 (PD-1), anti-programmed cell death\n             1 ligand 1(PD-L1), anti-PD-L2, anti-CD137 antibody, or anti-cytotoxic\n             T-lymphocyte-associated antigen-4 (CTLA-4) antibody\n\n          -  Known history of human immunodeficiency virus (HIV)\n\n          -  Known active Hepatitis B or Hepatitis C\n\n          -  Received live vaccine within 30 days prior to start of study treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "224", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01848834", 
            "org_study_id": "3475-012", 
            "secondary_id": [
                "2012-005771-14", 
                "142453"
            ]
        }, 
        "intervention": {
            "arm_group_label": [
                "Cohort A - Triple negative breast cancer", 
                "Cohort B - Head/neck cancer", 
                "Cohort C - Urothelial tract cancer", 
                "Cohort D - Gastric cancer", 
                "Cohort B2 - Head/neck cancer"
            ], 
            "intervention_name": "Pembrolizumab", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06520-8028"
                    }, 
                    "name": "Call for Information (Investigational Site 0005)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "Call for Information (Investigational Site 0003)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "Call for Information (Investigational Site 0004)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21231"
                    }, 
                    "name": "Call for Information (Investigational Site 0006)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "Call for Information (Investigational Site 0009)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19111"
                    }, 
                    "name": "Call for Information (Investigational Site 0007)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Call for Information (Investigational Site 0002)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Danny D'Hulster", 
                    "phone": "32 23734310"
                }, 
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium"
                    }, 
                    "name": "MSD Belgium BVBA/SPRL"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ofer Sharon", 
                    "phone": "972 9 9539310"
                }, 
                "facility": {
                    "address": {
                        "city": "Hod Hasharon", 
                        "country": "Israel"
                    }, 
                    "name": "Merck Sharp & Dohme Co. Ltd."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Japan Call Center", 
                    "phone": "81-3-6272-1957"
                }, 
                "facility": {
                    "address": {
                        "city": "Chiyoda-Ku, Tokyo", 
                        "country": "Japan", 
                        "zip": "102-8667"
                    }, 
                    "name": "MSD K.K."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Cem Ozesen", 
                    "phone": "90 212 3361260"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "MSD Korea LTD"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Israel", 
                "Japan", 
                "Korea, Republic of"
            ]
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors", 
        "other_outcome": {
            "measure": "Number of participants with log fold change from baseline in cytokines >1", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 8"
        }, 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of Participants Experiencing Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 90 days after last dose of study treatment (up to 2 years)"
            }, 
            {
                "measure": "Number of Participants Discontinuing from Study Treatment Due to Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to last dose of study treatment (up to 2 years)"
            }, 
            {
                "measure": "Overall Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Response Rate in Cohorts A,B,C, and D by Central Radiology Assessment", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Overall RECIST 1.1 Response Rate  by Investigator Assessment for PD-L1-negative Participants in Cohort B2", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "removed_countries": {
            "country": [
                "France", 
                "Canada"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01848834"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall RECIST 1.1 Response Rate by Central Radiology Assessment in Participants with Human Papilloma Virus (HPV)-positive Head and Neck Cancer", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Overall RECIST 1.1 Response Rate by Central Radiology Assessment in Asia Pacific Participants with Gastric Cancer", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Overall RECIST 1.1 Response Rate by Investigator Assessment for Cohort B2", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Overall RECIST 1.1 Response Rate by Investigator Assessment for Participants in Cohorts A,B,C, and D", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}